Author

Xiaoling Shang

Observed name: Shang, Xiaoling

Institutions: Hebei North University, Shandong Tumor Hospital, Qilu Hospital of Shandong University, Shandong First Medical University

Observed institutions: Shandong University, Hebei North University, Shandong Tumor Hospital, Qilu Hospital of Shandong University, Shandong First Medical University

ORCID: 0009-0007-4954-1173

Observed ORCID: 0009-0007-4954-1173

OpenAlex ID: A5126106673

Spatial transcriptomics of immune ecotypes for predicting immunotherapy outcomes in head and neck squamous cell carcinoma

2026 · Yunchao Xin, Lihang Yang, et al. · Oral Oncology · 5

Dual PD-1/IL-2Rα targeting restores CD8+ T cell fitness via STAT5/CD47 axis in SMARCA4-deficient NSCLC

2026 · Xiaoling Shang, Bo Cheng, et al. · Cell Reports Medicine · 3

Spatial and maturational characterisation of tertiary lymphoid structures predicts immunotherapy response in extensive‐stage small cell lung cancer

2026 · Haoyu Wang, Xiaoling Shang, et al. · Clinical & Translational Immunology

Dynamic Granulocyte Turnover Inferred From cfDNA Methylation Predicts Immunotherapy Benefit in Liver‐Metastatic Small Cell Lung Cancer: A Prospective Biomarker Study

2026 · Ning Tang, Xiaoling Shang, et al. · MedComm

Mesenchymal stem cells promote cisplatin resistance in non-small cell lung cancer through IL-6/MEK-ERK/macrophages axis: construction of prognostic signature and experimental investigation

2026 · Xinchun Ma, Zhihui Zhang, et al. · Frontiers in Pharmacology

Works count: 9

Citation count: 8

H-index: 2

I10-index: